<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206866</url>
  </required_header>
  <id_info>
    <org_study_id>SMP30</org_study_id>
    <nct_id>NCT03206866</nct_id>
  </id_info>
  <brief_title>Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma</brief_title>
  <official_title>Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the diagnosis and therapy of HCC have being improved, the poor prognosis still
      remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it
      is important to detect the protein biomarkers which are associated with HCC tumor progression
      and may be useful as potential diagnosis or therapeutic targets.

      SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identiÔ¨Åed
      from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular
      carcinoma associated antigens [4]

      Serum antibody response to SMP30 in various patients using the methods of Western-blot and
      ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in
      the one with alpha-fetoprotein (AFP) negative
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>serum regucalcin in HCC patients</measure>
    <time_frame>1-12-2016 to 1-12-2017</time_frame>
    <description>This work aims to assess serum regucalcin antibodies level using ELISA in HCC patients to:
evaluate its potential role as biomarker in diagnosis.
evaluate potential associations of the presence of serum regucalcin antibody with HCC patients' clinico-epidemiological parameters.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Role of Serum Regucalcin in Diagnosis of HCC</condition>
  <arm_group>
    <arm_group_label>patients with HCC</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with hepatitis C Ab positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with hepatitis C Ab negative</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum regucalcin antibody</intervention_name>
    <description>serum regucalcin antibody</description>
    <arm_group_label>patients with HCC</arm_group_label>
    <arm_group_label>patients with hepatitis C Ab positive</arm_group_label>
    <arm_group_label>patients with hepatitis C Ab negative</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients will be subjected to the following:

          -  Detailed History taking.

          -  Physical examination.

          -  Routine laboratory investigations essential for diagnosis and follow up of patients
             including:

               1. Complete blood count (CBC).

               2. Chemistry profile: serum bilirubin-serum albumin-SGPT-SGOT.

               3. serum regucalcin(SMP30) antibodies using ELISA

               4. AFP level.

          -  Radiological assessment:

        US, Triphasic CT to assess (tumor site, size, numbers, nodal metastases, distal metastases,
        portal vein invasion..)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or
             liver biopsy)

          2. Adult patients

          3. Both genders are eligible.

          4. Informed consent obtained from subject or subject's legal representative

        Exclusion Criteria:

          1. Patient with other malignancies.

          2. Patients with advanced comorbidities except for renal failure.

          3. Prior chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oncology Center Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>maha zaafarany, professor</last_name>
      <phone>01001996798</phone>
    </contact>
    <contact_backup>
      <last_name>sameh samaa, professor</last_name>
      <phone>01001009510</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://ocmu.mans.edu.eg/en/</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Ahmed_Elalfy</investigator_full_name>
    <investigator_title>medical oncology resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

